OR WAIT null SECS
Selexis will be integrated with KBI Biopharma, which was acquired by JSR Life Sciences in 2015.
On June 14, 2017, JSR Life Sciences announced that it has agreed to acquire Selexis SA, a life-sciences company specializing in mammalian cell-line generation technologies. This will mark the second major biotechnology addition to the company, following JSR Corporation’s acquisition of KBI Biopharma in 2015, the company said in a press release. Selexis will be integrated within KBI Biopharma’s operations. The financial terms of the agreement were not disclosed.
“Combining KBI’s robust analytical, process development, and reliable high-quality manufacturing capabilities with our Selexis SUREtechnology Platform, puts us in a position to offer current and future partners the ability to take their R&D programs from transfection to investigational new drug (IND) application in less than nine months,” said Igor Fisch, PhD, CEO, Selexis, in a statement. “By delivering the fastest timelines in the industry, our partners will benefit from substantial cost savings and patients will have access to critical drugs sooner. We believe in the ability of our combined technologies and knowhow to contribute to the medicines of tomorrow that will save the lives of those facing diseases as diverse as HIV and various cancers.”
Source: JSR Life Sciences